Anticholinergic use in hospitalised schizophrenic patients in Belgium

Psychiatry Research

Volumn 152, Issue 2-3, 2007, Pages 165-172

  De Hert, Marc ^a   Wampers, Martien ^a   van Winkel, Ruud ^a   Peuskens, Jozef ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antipsychotics; Schizophrenia; Side effects

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; BELGIUM; CATATONIC SCHIZOPHRENIA; DISEASE DURATION; DRUG POTENCY; DRUG USE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEBEPHRENIA; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PRIORITY JOURNAL; RESIDUAL SCHIZOPHRENIA; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BELGIUM; CATCHMENT AREA (HEALTH); CHOLINERGIC ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; FEMALE; HOSPITALIZATION; HUMANS; MALE; SCHIZOPHRENIA;

EID: 34547690933     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2006.07.012     Document Type: Article

References (40)

1. Arvanitis L.A., and Miller B.G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biological Psychiatry 42 (1997) 233-246
2. Baldessarini R.J., Cohen B.M., and Teicher M.H. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45 (1988) 79-91
3. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., and Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124 (1996) 159-167
4. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., and Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14 (1996) 111-123
5. Copolov D.L., Link C.G., and Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204, 636, 'Seroquel') and haloperidol in schizophrenia. Psychological Medicine 30 (2000) 95-105
6. Csernansky J.G., Mahmoud R., and Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine 346 (2002) 16-22
7. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60 (2003) 553-564
8. De Hert M., Wampers M., Thys E., Wieselgren I., Lindström E., and Peuskens J. Validation of PECC, interscale validity and interrater reliability. International Journal of Psychiatry in Clinical Practice 6 (2002) 135-140
9. Farde L., Mack R.J., Nyberg S., and Haldin C. D2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. International Journal of Clinical Psychopharmacology 12 Suppl. 1 (1997) S3-S7
10. Fleischhacker W.W., Oehl M.A., and Hummer M. Factors influencing compliance in schizophrenia patients. Journal of Clinical Psychiatry 64 Suppl 64 (2003) 10-13
11. Gallhofer B., Bauer U., Gruppe H., Krieger S., and Lis S. First episode schizophrenia: the importance of compliance and preserving cognitive function. Journal of Psychiatry and Behavioral Health 22 (1996) 16S-24S
12. Gold J.M., Carpenter C., Randolph C., and Goldberg T.E. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Archives of General Psychiatry 54 (1997) 159-165
13. Goldberg T.E., Weinberger D.R., Pliskin N.H., Berman K.F., and Podd M.H. Recall memory deficit in schizophrenia. A positive manifestation of frontal dysfunction. Schizophrenia Research 2 (1989) 251-257
14. Goldberg T.E., Hyde T.M., Kleinman J.E., and Weinberger D.R. Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophrenia Bulletin 19 (1993) 797-804
15. Kane J.M. Newer antipsychotic drugs. A review of their pharmacological and therapeutic potential. Drugs 46 (1993) 585-593
16. Kane J.M. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Journal of Clinical Psychiatry 64 Suppl 16 (2003) 34-40
17. Kane J.M. PORT recommendations. Schizophrenia Bulletin 30 (2004) 605-607
18. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. Expert consensus guideline series. Optimising pharmacologic treatment of psychotic disorders. Introduction: methods, commentary and summary. Journal of Clinical Psychiatry 64 Suppl 12 (2003) 5-19
19. Kapur S., Roy P., Daskalakis J., Remington G., and Zipursky R. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. American Journal of Psychiatry 158 (2001) 311-314
20. Kelly G.R., Mamon J.A., and Scott J.E. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Social Science & Medicine 25 (1987) 1205-1211
21. Kennedy J.S., Bymaster F.P., Basson B.R., Gilmore J.A., and Tran P.V. The comparative peripheral anticholinergic-like adverse event profiles of olanzapine and risperidone. Journal of Clinical Psychiatry 2 (2000) 122-126
22. Kulkarni J., and Power P. Initial treatment of first-episode psychosis. In: McGorry P., and Jackson H. (Eds). The Recognition and Management of Early Psychosis (1999), University Press, Cambridge
23. Lehman A.F., Kreyenbuhl J., Buchanan R.W., Dickerson F.B., Dixon L.B., Goldberg R., Green-Paden L.D., Tenhula W.N., Boerescu D., Tek C., Sandson N., and Steinwachs D.M. The Schizophrenia Patient Outcome Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30 (2004) 193-217
24. Leucht S., Barnes T.R.E., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomised controlled trials. American Journal of Psychiatry 160 (2003) 1209-1214
25. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 (2005) 1209-1223
26. Marder S.R. Overview of partial compliance. Journal of Clinical Psychiatry 64 Suppl 16 (2003) 3-9
27. Marder S.R., and Meibach R.C. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 151 (1994) 825-835
28. Marder S.R., Mebane A., Chien C.P., Winslade W.J., Swann E., and Van Putten T. A comparison of patients who refuse and consent to neuroleptic treatment. American Journal of Psychiatry 140 (1983) 470-472
29. Meltzer H.Y. Action of atypical antipsychotics. American Journal of Psychiatry 159 (2002) 153-154
30. NICE (National Institute for Clinical Excellence). Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia (2002)
31. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. British Journal of Psychiatry 166 (1995) 712-726
32. Rosenheck R., Perlick D., Bingham S., Liu-Marcs W., Collins J., Warren S., Leslie D., Allan E., Campbell E.C., Caroff S., Corwin J., Davis L., Douyon R., Dunn L., Evans D., Frecska E., Grabowski J., Graeber D., Herz L., Kwon K., Lawson W., Mena F., Sheikh J., Smelson D., and Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 290 (2003) 2693-2702
33. Schwartz B.L., Rosse R.B., and Deutsch S.I. Toward a neuropsychology of memory in schizophrenia. Psychopharmacology Bulletin 28 (1992) 341-351
34. Small J.G., Hirsch S.R., Arvanitis L.A., Miller B.G., and Link C.G. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Archives of General Psychiatry 54 (1997) 549-557
35. Taylor D., Mace S., Mir S., and Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. International Journal of Psychiatry in Clinical Practice 4 (2000) 41-46
36. Taylor D., Mir S., and Kerwin R. Prescribing in schizophrenia. Evaluating the effect of introducing a new treatment protocol. Psychiatric Bulletin 24 (2000) 106-108
37. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., and Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 154 (1997) 1248-1254
38. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M., Potvin J.H., and Kiesler G.M. Extrapyramidal symptoms and tolerability ol olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry 58 (1997) 205-211
39. World Health Organisation. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. British Journal of Psychiatry 156 (1990) 412
40. Yurgelun-Todd D.A., and Waternaux C.S. Cognitive deficits underlying verbal memory function in schizophrenic patients and controls. Schizophrenia Research 4 (1991) 396-397